Cogent Biosciences Inc. Announces Positive Results from SUMMIT Trial, Plans NDA Submission for Bezuclastinib by End of 2025

Reuters
07 Jul
<a href="https://laohu8.com/S/COGT">Cogent Biosciences</a> Inc. Announces Positive Results from SUMMIT Trial, Plans NDA Submission for Bezuclastinib by End of 2025

Cogent Biosciences Inc. announced on July 7, 2025, that it has achieved positive top-line results from Part 2 of the SUMMIT clinical trial for bezuclastinib in patients with non-advanced systemic mastocytosis. These results demonstrate clinically meaningful improvements across primary and secondary endpoints, strengthening the company's plan to submit a new drug application to the U.S. FDA by the end of 2025. The SUMMIT trial results will be detailed at a major medical conference later this year. Additionally, Cogent Biosciences is on track to release top-line results for its ongoing PEAK and APEX trials in the latter half of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-155811), on July 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10